Covid-19 vaccine approvals and stock market returns: the case of Chinese stocks
From MaRDI portal
Publication:2158358
DOI10.1016/J.ECONLET.2022.110466zbMATH Open1493.91119OpenAlexW4220899912MaRDI QIDQ2158358FDOQ2158358
Authors: Yi-Bo Gao, Qiying Gu, Da Yang, Ken-Chung Ho
Publication date: 26 July 2022
Published in: Economics Letters (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.econlet.2022.110466
Recommendations
- Stay-at-home stocks versus go-outside stocks: the impacts of COVID-19 on the Chinese stock market
- Many hands make light work: evidence from China's anti-epidemic bonds
- COVID-19: what is going on with the stock market in Vietnam
- Kindness is rewarded! The impact of corporate social responsibility on Chinese market reactions to the COVID-19 pandemic
- Developed and emerging stock markets volatility during the global pandemic of coronavirus disease 2019 (COVID-19): dynamic correlation approach
Cites Work
Cited In (5)
- Study on announcement effect of stock repurchase from the perspective of configuration analysis
- The stock performance of green bond issuers during COVID-19 pandemic: the case of China
- Stay-at-home stocks versus go-outside stocks: the impacts of COVID-19 on the Chinese stock market
- Many hands make light work: evidence from China's anti-epidemic bonds
- COVID-19: what is going on with the stock market in Vietnam
This page was built for publication: Covid-19 vaccine approvals and stock market returns: the case of Chinese stocks
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2158358)